Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | PDE5A | O76074 | 2/20 | 0.34 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.32 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23577174 | 1.00 | MAPT (0.35) | MAPTSMN1; SMN2PDE5ACSNK2A2CSNK2B | |
| SCHEMBL30961002 | 0.91 | MAPT (0.35) | MAPTSMN1; SMN2PDE5ACSNK2A2CSNK2B | |
| SCHEMBL23576806 | 0.91 | MAPT (0.35) | MAPTSMN1; SMN2PDE5ACSNK2A2CSNK2B | |
| SCHEMBL23577290 | 0.89 | CSNK2A1 (0.37) | MAPTSMN1; SMN2PDE5ACSNK2A2CSNK2B | |
| SCHEMBL29909900 | 0.89 | CSNK2A1 (0.37) | MAPTSMN1; SMN2PDE5ACSNK2A2CSNK2B | |
| SCHEMBL23576970 | 0.83 | POLB (0.39) | MAPTSMN1; SMN2PDE5APOLBKDM4E | |
| SCHEMBL30961052 | 0.83 | POLB (0.39) | MAPTSMN1; SMN2PDE5APOLBKDM4E | |
| SCHEMBL23576921 | 0.82 | PDE5A (0.36) | MAPTSMN1; SMN2PDE5ACSNK2A2CSNK2B | |
| SCHEMBL23578049 | 0.82 | ABCG2 (0.42) | SMN1; SMN2PDE5A | |
| SCHEMBL23578069 | 0.82 | EGFR (0.47) | MAPTSMN1; SMN2PDE5ACSNK2A2CSNK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4445902-A2 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | Carna Biosciences, Inc. (JP) | 2024-10-16 | — | — | EP | disclosed |
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| CN-118324767-A | Diacylglycerol kinase modulating compounds | 卡尔那生物科学株式会社 | 2024-07-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | DGKG, DGKB, DGKK | MAPT 4206/4885SMN1; SMN2 4737/4885PDE5A 1924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.